(Q44319954)

1 December 2017

title

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy (English)

1 reference

1 December 2017

0 references

1 reference

1 reference

6

1 reference

1 December 2017

7

1 reference

1 December 2017

1

Selma Ugurel

1 reference

1 December 2017

4

Dirk Schadendorf

1 reference

1 December 2017

5

Eva-Bettina Bröcker

1 reference

1 December 2017

10

Jürgen C Becker

1 reference

1 December 2017

2

David Schrama

1 reference

1 December 2017

Gunhild Keller

3

1 reference

1 December 2017

Wolfram Fink

series ordinal

8

1 reference

1 December 2017

Howard L Kaufman

series ordinal

9

1 reference

1 December 2017

publication date

2 October 2007

1 reference

Cancer Immunology, Immunotherapy

1 December 2017

published in

1 reference

1 December 2017

volume

57

1 reference

1 December 2017

issue

5

1 reference

1 December 2017

page(s)

685-691

1 reference

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Beyond unfractionated heparin and warfarin: current and future advances

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

New anticoagulants for treatment of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

The Mark Coventry Award: Prevention of readmission for venous thromboembolism after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Structure-based design of novel potent nonpeptide thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.5.685

21 January 2018

Identifiers

DOI

10.2217/14750708.5.5.685

1 reference

1 December 2017

1 reference